---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-051209"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:52:51.808242+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded

## Summary
- Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.
- Conversion price lower of $2.41/share or 94% of 5-day VWAP; 0% interest (18% upon default), matures Dec 2025.
- Additional $10M common stock purchase commitment available under SEPA over two years, subject to Yorkville's consent.
- CEO states proceeds will fund first-in-human diabetic foot ulcer trial and psoriasis IND-enabling studies.
- Shareholder approval required for issuances exceeding 19.99% of outstanding shares (Exchange Cap).

## SEC filing metadata
- accession: 0001493152-24-051209
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/0001493152-24-051209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-051209
- JSON: https://secwatch.observer/filing/0001493152-24-051209.json
- Plain text: https://secwatch.observer/filing/0001493152-24-051209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.